Journal article

Antibody-Drug Conjugates for Cancer Therapy

Umbreen Hafeez, Sagun Parakh, Hui K Gan, Andrew M Scott

Molecules | MDPI | Published : 2020

Abstract

Antibody-drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows and enhanced pharmacokinetic/pharmacodynamic properties. To date, nine ADCs have been approved by the FDA and more than 80 ADCs are under clinical development worldwide. In this paper, we provide an overview of the biology and chemistry of each component of ADC design. We briefly discuss the clinical experience with approved ADCs and the various..

View full abstract

Grants

Awarded by NHMRC


Awarded by Cancer Council of Victoria


Awarded by NHMRC Investigator Fellowship


Funding Acknowledgements

This review was supported in part by grants from NHMRC (No. 1092788), the Cancer Council of Victoria (No. 1164229) and the Operational Infrastructure Support Program provided by the Victorian Government and is acknowledged. Andrew Scott is supported by an NHMRC Investigator Fellowship (No. 1177837).